What’s in a Name?: Endpoint Health’s Patient-Centric Northstar with Jason Springs | Podcast #27
Welcome to Talking Precision Medicine — the podcast in [...]
Genialis’ ResponderID™ Named a Fast Company 2022 World Changing Idea
The winners of Fast Company’s 2022 World Changing Ideas [...]
Genialis Renews ISO 27001 Certification for Fifth Year Running
Renewed credentials underscore the computational precision medicine company’s commitment to [...]
Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Navicixizumab plus paclitaxel demonstrated promising clinical activity in bevacizumab-treated and -naive patients with platinum-resistant ovarian cancer, with manageable toxicity.
Genialis Releases Improved Version of Expressions for Faster, More Secure Multi-Omics Processing and Data Management
Cloud software for bioinformatics and systems biology is relaunched [...]
Xerna™ TME Panel: A pan-cancer RNA-based investigational assay designed to predict patient response to angiogenic- and immune-targeted therapies
The Xerna™ TME Panel is a pan-cancer RNA-based investigational [...]
Genialis ResponderID to Use Xerna™ TME Panel to Improve Targeted Therapy Selection
Biomarker discovery platform will incorporate pan-cancer tumor microenvironment classifier [...]
Inhibrx Selects Genialis ResponderID™ for Clinical Optimization Study of INBRX-109
Machine Learning technology platform to be evaluated for potential [...]
Taking charge of your health future with wearables and AI with Harry Glorikian | Podcast #26
Welcome to Talking Precision Medicine — the podcast in [...]
Genialis AI platform speeds identification of biomarkers
Cancer trials that stratify patients using biomarkers increase their [...]
